Randal J. Kirk
Chairman and Chief Executive Officer, Intrexon
Mr. Kirk was named Chairman of Intrexon in February 2008 and was appointed Chief Executive Officer in April 2009. Mr. Kirk also serves on the Board of Directors of Halozyme Therapeutics, Inc. (NASDAQ: HALO) as well as the Board of Directors of ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP). In addition, Mr. Kirk is Senior Managing Director and Chief Executive Officer of Third Security, LLC, an investment management firm which he founded. Prior to Intrexon, Mr. Kirk was Chairman of the Board of Clinical Data, Inc., until the NASDAQ-listed company was acquired by Forest Laboratories, Inc., in April 2011. Mr. Kirk was also Chairman of the Board and Chief Executive Officer of New River Pharmaceuticals Inc., a specialty biopharmaceutical company he founded in 1996, until its acquisition by Shire plc in April 2007. Mr. Kirk has also previously served on the Board of Directors of Scios Inc., the Board of Directors of the Radford University Foundation, the Board of Visitors of Radford University, the Board of Visitors of the University of Virginia and Affiliated Schools, the Virginia Advisory Council on Revenue Estimates, and the Governor's Economic Development and Jobs Creation Commission. Mr. Kirk began his professional career in the private practice of law. Mr. Kirk received a B.A. in Business from Radford University and a J.D. from the University of Virginia.